The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2024 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 USD | -1.59% | -9.49% | 0.00% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2024 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
0.00% | 260M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+3.52% | 22.25B | |
-14.77% | 21.68B | |
-7.38% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |